Acesso livre
Acesso livre

Farmácia/Notícias da Indústria

OMS | Segundo reforço da vacina contra COVID para os mais vulneráveis oferece benefícios.

19 Mai, 2022 | 13:15h

WHO: 2nd COVID booster for most vulnerable offers benefits – World Health Organization

[Preprint] Efetividade do segundo reforço da vacina contra COVID-19 sobra a mortalidade por todas as causas em residentes de instituições de cuidado de longo prazo e em idosos mais velhos: estudo nacional de coorte retrospectiva na Suécia.

19 Mai, 2022 | 13:13h

Effectiveness of a Second COVID-19 Vaccine Booster on All-Cause Mortality in Long-Term Care Facility Residents and in the Oldest Old: A Nationwide, Retrospective Cohort Study in Sweden – Preprints with The Lancet

 

Comentário no Twitter

 

Tratamento das interações medicamentosas com nirmatrelvir/ritonavir (Paxlovid).

19 Mai, 2022 | 13:08h

Management of Drug Interactions With Nirmatrelvir/Ritonavir (Paxlovid®): Resource for Clinicians – Infectious Diseases Society of America

Comentário: IDSA offers guidance on managing drug interactions with nirmatrelvir/ritonavir – ACP Internist

Conteúdos relacionados:

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic – STAT

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

Covid-19: What is the evidence for the antiviral Paxlovid? – The BMJ

Yes, Relapses After Paxlovid Happen — Now What? – HIV and ID Observations

WHO recommends highly successful COVID-19 therapy and calls for wide geographical distribution and transparency from originator – World Health Organization

A living WHO guideline on drugs for covid-19 – The BMJ

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Prescribing Nirmatrelvir–Ritonavir: How to Recognize and Manage Drug–Drug Interactions – Annals of Internal Medicine

The COVID-19 Treatment Guidelines Panel’s Statement on Potential Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications – NIH COVID-19 Treatment Guidelines Panel

M-A | Agonistas receptores do peptídio-1 glucagon-like (GLP-1) e eventos cardiovasculares em pacientes com diabetes melito tipo 2.

19 Mai, 2022 | 13:03h

Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials – BMC Endocrine Disorders

 

Comentário no Twitter

Sob licença de http://creativecommons.org/licenses/by/4.0/

Revisão | Papel dos anticoagulantes orais diretos na profilaxia de tromboembolismo venoso pós-operatório.

19 Mai, 2022 | 12:57h

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis – European Cardiovascular Review

 

Comentário no Twitter

Sob licença de CC-BY-NC 4.0

M-A | Avaliação do risco de eventos cardiovasculares por uso de tirzepatida.

19 Mai, 2022 | 12:41h

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Comentário: Meta-analysis backs tirzepatide CV safety – medwireNews

 

Comentário no Twitter

 

Sinopse de diretriz | Terapia antitrombótica para tromboembolismo venoso.

18 Mai, 2022 | 17:04h

Antithrombotic Therapy for Venous Thromboembolism – JAMA (gratuito por tempo limitado)

Diretriz original: Antithrombotic Therapy for VTE Disease

Second Update of the CHEST Guideline and Expert Panel Report

Pontos EULAR a considerar para o monitoramento de terapia medicamentosa com biofarmacêuticos em doenças inflamatórias reumáticas e musculoesqueléticas.

18 Mai, 2022 | 16:51h

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases – Annals of Rheumatic Diseases

 

Comentário no Twitter

 

Estudo randomizado | Antibioticoprofilaxia de longa duração na amputação de membro inferior.

18 Mai, 2022 | 16:49h

Extended-course antibiotic prophylaxis in lower limb amputation: randomized clinical trial – British Journal of Surgery (link para o resumo – $ para o texto completo)

 

Comentário no Twitter

 

Comentário de estudo | Antibióticos para pneumonia pediátrica: menos pode ser suficiente?

18 Mai, 2022 | 16:42h

Antibiotics for Pediatric Pneumonia: Might Less Be Enough? – Annals of Emergency Medicine

Estudo original: Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial – JAMA

Conteúdos relacionados:

Extended Versus Standard Antibiotic Course Duration in Children <5 Years of Age Hospitalized With Community-acquired Pneumonia in High-risk Settings: Four-week Outcomes of a Multicenter, Double-blind, Parallel, Superiority Randomized Controlled Trial – The Pediatric Infectious Disease Journal

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial – JAMA Pediatrics

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians – Annals of Internal Medicine

Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial – JAMA Pediatrics

Treatment of UTIs in Infants <2 Months: A Living Systematic Review – Hospital Pediatrics

Effect of 7 vs 14 Days of Antibiotic Therapy on Resolution of Symptoms Among Afebrile Men With Urinary Tract Infection: A Randomized Clinical Trial – JAMA

Seven versus fourteen Days of Antibiotic Therapy for uncomplicated Gram-negative Bacteremia: a Non-inferiority Randomized Controlled Trial – Clinical Infectious Diseases

Efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults: A systematic review and meta-analysis – Antimicrobial Agents and Chemotherapy

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.